Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-Spectroscopy Neurochemical Changes in Migraineurs Before and After Fremanezumab
2024-517079-19-00Phase 4Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fremanezumab in migraine (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Primary: Difference in neurotransmitter level in the occipital cortex before and after 12 weeks of CGRP antibody treatment. Started Feb 2022; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-517079-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517079-19-00.